EXACT Sciences — Investor Presentation (January 2008)
15 slides from EXACT Sciences's investor presentation, Jan 4, 2008
Slide 1: Applying Genomics to Eradicate Cancer Mortality
Applying Genomics to Eradicate Cancer Mortality
Slide 2: Safe Harbor
Safe Harbor Certain matters we will discuss today, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to, among other things, our expectations concerning the timing of p
Slide 3: Colorectal Cancer (CRC)
Colorectal Cancer (CRC) • Most deadly cancer beyond lung cancer • Affects men & women equally • 154,000 cases diagnosed; 52,000 deaths annually • ACS recommends people 50+ yrs. get screened • Screening technologies available for 20+ yrs; screening rates have improved only slightly • 2/3 diagnosed la
Slide 4: CRC Screening – Significant Unmet Need
CRC Screening – Significant Unmet Need Non-compliant ~65M People ~22M Compliant 87M People in the US over age 501 Traditional screening methods are not enough 1 U.S. Census Bureaus, May 2006
Slide 5: Strategic Advantages of EXACT Sciences
Strategic Advantages of EXACT Sciences • Non-invasive technology • Designed for mass use – rural and urban access • Molecular biology of CRC is well known • Proprietary DNA-based technology identifies direct changes associated with CRC NOT indirect • Strong IP position / Exclusive from Johns Hopkins
Slide 6: LabCorp Advantage
LabCorp Advantage • Pioneer in genomic testing and commercialization of new diagnostic technologies • One of the largest labs in U.S. – $3.6B annual revenue – 350,000+ tests processed/day – ~1,000 sales reps – Numerous payor contracts • $30M+ in license fees/milestones paid to date
Slide 7: DNA Technology: A test people will actually use
• Non-invasive • Single stool specimen collected at home • No sample manipulation • No bowel preparation • No time off from work • No medication/dietary restrictions • DNA has a positive connotation among patients 4X higher cancer detection rate than most widely used, non-invasive test, FOBT (NEJM,
Slide 8: Clinical Utility
Clinical Utility Colonoscopy sDNA Flex Sig FOBT Distribution / Access Compliance Accuracy Adapted from David Ahlquist, M.D., Mayo Clinic
Slide 9: Key Achievements
Developed non-invasive DNA technology for CRC Established US license relationship w/ LabCorp Demonstrated 4X superiority over widely used FOBT Developed higher sensitivity Version 2 technology Included in International Screening Guidelines Key Achievements
Slide 10: Version 2.0 DNA Technology
Version 2.0 DNA Technology • Recently completed large multi-center study on V2 • Interim data on 40 cancers was published, 1/07; 88% sensitivity, 82% specificity • Final results showed sensitivity AGAIN in 80s – 82 CRC patients and 363 colonoscopy normal individuals – 83% sensitivity, 82% specificit
Slide 11: Near-Term Focus
Near-Term Focus • Inclusion in American Cancer Society & U.S. Multi-Society Task Force on Colorectal Cancer (MSTF-CRC) screening guidelines – Guidelines drafted – Currently being circulated among MSTF-CRC members – Do not know specific timeframe for release • FDA approval on DNA technologies • Medic
Slide 12: FDA Update
FDA Update Two goals of FDA strategy – Version 1 compliance – Version 2 approval • V1 regulatory proposal – Met with FDA 10/26/07; presented 510(k) filing strategy – Submitted pre-IDE 11/2/07 – Received FDA feedback on pre-IDE • Next step is to meet with FDA to discuss feedback • V2 regulatory propo
Slide 13: Financial Summary as of 9/30/07
Financial Summary as of 9/30/07 • $14.8M in cash – Sufficient for operations through 2008 – May change based on FDA feedback and requirements • LabCorp deal – $30M in license fees/milestones paid to date – $42.5M in potential milestones upon achievement of significant sales thresholds – 15%-17% roya
Slide 14: Summary – Key Focus
Summary – Key Focus • Inclusion in American Cancer Society screening guidelines • FDA approval • Medicare approval
Slide 15: Applying Genomics to Eradicate Cancer Mortality
Applying Genomics to Eradicate Cancer Mortality
EXACT Sciences — Investor Presentation (January 2008) on 6ix